atorvastatin/fenofibrate / Generic mfg. - LARVOL DELTA

Need for Medication Review and Deprescribing in People Living with HIV: A Longitudinal Observational Study. (PubMed, Pharmaceuticals (Basel)) - "Four were DDIs: cobicistat/alprazolam associated with sedation and dyspnoea, rilpivirine/hydroxychloroquine with QT prolongation, bictegravir/ursodeoxycholic acid with rising viremia, and atorvastatin/fenofibrate with myalgia...After medication review, alprazolam was replaced with zolpidem, rilpivirine-based HAART with bictegravir/emtricitabine/tenofovir alafenamide, and atorvastatin/fenofibrate with simvastatin/ezetimibe, and ursodeoxycholic acid and supplements were discontinued... This study highlights the importance of predicting DDIs/DSIs in PLWH undergoing polypharmacy. Medication review supports clinical decision-making, preventing avoidable adverse outcomes."

Journal • Observational data • Anesthesia • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Pain • Pain • Pulmonary Disease

Splenic Vein Thrombosis Complicating Hypertriglyceridemia-Induced Acute Pancreatitis in Diabetic Ketoacidosis: A Rare Clinical Tetrad. (PubMed, Cureus) - "Therapeutic intravenous heparin was initiated, followed by transition to oral apixaban. He was discharged in stable condition on basal-bolus insulin, atorvastatin, fenofibrate, and omega-3 acid ethyl esters with multidisciplinary follow-up. This case describes a rare clinical tetrad linking DKA, severe HTG, HTG-AP, and SVT. It highlights the importance of early recognition and prompt multidisciplinary management of both the metabolic and thrombotic complications associated with this uncommon presentation."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Pain • Pancreatitis • Portal Hypertension • Severe Hypertriglyceridemia • Thrombosis • Type 2 Diabetes Mellitus

Study on the mechanism of bezafibrate, fenofibrate and atorvastatin calcium inhibiting doxorubicin-induced ferroptosis in heart failure cells (ESC 2026) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants. (PubMed, Transl Clin Pharmacol) - "Plasma concentrations of atorvastatin and 2-hydroxy (2-OH) atorvastatin were measured for 48 h in all periods, and fenofibric acid for 72 hours in the first two periods. The findings support its use as an alternative to improve medication adherence in patients with mixed dyslipidemia requiring dual lipid-modifying therapy. Clinical Research Information Service Identifier: KCT0010666."

Journal • PK/PD data • Cardiovascular • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

A Patch Too Far: Severe Hypertriglyceridemia-Induced Pancreatitis Triggered by Transdermal Estrogen (ENDO 2026) - "Her symptoms improved, and she was discharged on fenofibrate and atorvastatin. Conclusion Transdermal estrogen is not entirely metabolically neutral and can precipitate severe hypertriglyceridemia and pancreatitis in susceptible individuals. Consideration should be given to baseline lipid assessment and clinical risk stratification prior to initiation in high-risk patients."

Late-breaking abstract • Dyslipidemia • Gastroenterology • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Polyendocrine Metabolic Ovarian Syndrome • Severe Hypertriglyceridemia • LPL

Fasting Is (More) Furious: Management of Asymptomatic Severe Hypertriglyceridemia with Diet (ENDO 2026) - "After TG reached 983 mg/dL, the patient was discharged on SQ insulin, fenofibrate, atorvastatin, and omega-3. Conclusion This case demonstrates the varying effects of diet, IV, and SQ insulin, and that fasting potentially may be the most cost effective and clinically significant method of improving TG levels in an asymptomatic patient. Potential avoidance of ICU stays and hospital admissions could be considered in a patient who is able to be compliant with fasting only in asymptomatic severe HTG."

Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus

Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk. (PubMed, Front Endocrinol (Lausanne)) - "From 20 RCTs, Cerivastatin best reduced Total Cholesterol (TC) (Mean Difference (MD): -94.03, 95% CI: -185.37 to -2.16), while Simvastatin best lowered Low-Density Lipoprotein Cholesterol (LDL-C) (MD: -56.05, 95% CI: -101.64 to -11.66). Lipid-lowering agents have divergent effects; Atorvastatin and Fenofibrate best reduce CVER despite variable renal effects, supporting a phenotype-driven CRM strategy prioritizing residual cardiovascular risk reduction. https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420251049719."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Diabetic Nephropathy • Dyslipidemia • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease

DUAL-MODALITY MANAGEMENT OF FAMILIAL CHYLOMICRONEMIA SYNDROME: OLEZARSEN AND APHERESIS IN ACTION (ACC 2026) - "After starting Atorvastatin, Fenofibrate, and apheresis biweekly in 2017, his triglyceride levels stabilized between 800-1200 mg/dL on average for several years. This case demonstrates the potential benefit of combing Olezarsen with apheresis in FCS, balancing clinical outcomes and patients' quality of life."

Familial Chylomicronemia Syndrome • Pancreatitis

Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components. (PubMed, Clin Pharmacol Drug Dev) - "For fenofibric acid, the corresponding values were 0.9896 (0.8810-1.1116) and 0.9871 (0.8869-1.0986), respectively. The FDC of atorvastatin/fenofibrate 20/145 mg showed comparable PK profiles to the corresponding individual components, supporting its potential as an alternative therapeutic option for dyslipidemia with convenience."

Clinical • Journal • PK/PD data • Dyslipidemia • Metabolic Disorders

Alternate-day alternating monotherapy (q48h) versus daily concomitant atorvastatin-fenofibrate in adults with type 2 diabetes and mixed dyslipidemia: a 12-week randomized non-inferiority trial. (PubMed, BMC Endocr Disord) - "Over 12 weeks, Alternating monotherapy (q48h) was non-inferior to Daily concomitant atorvastatin-fenofibrate for LDL-C lowering, with similar secondary outcomes and acceptable tolerability. Findings support clinical feasibility of a simplified alternate-day schedule; no formal economic analysis was performed. Longer studies with objective adherence assessment are warranted."

Head-to-Head • Journal • Monotherapy • Diabetes • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia • Type 2 Diabetes Mellitus

Diabetic Ketoacidosis Unveiling Severe Hypertriglyceridemia and Acute Mild Pancreatitis: A Rare Initial Manifestation of Type 2 Diabetes Mellitus. (PubMed, Am J Case Rep) - "He was subsequently transitioned to subcutaneous insulin; atorvastatin and fenofibrate were initiated for long-term lipid control. Prompt diagnosis and protocol-based management can substantially improve outcomes in such patients. Increased clinician awareness is essential to optimize care in similar cases."

Journal • Diabetes • Dyslipidemia • Endocrine Disorders • Gastroenterology • Hypertriglyceridemia • Metabolic Disorders • Pain • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus

Screening, Diagnosis, and Treatment of Cardiometabolic Risk in Persons With Spinal Cord Injury/Disease: A Scoping Review. (PubMed, Arch Rehabil Res Clin Transl) - "Four studies (14.8%) evaluated different pharmacologic treatments (atorvastatin, fenofibrate, α-lipoic acid, semaglutide) to target CMD risk factors. Sociodemographic reporting was poor across all study types, highlighting a gap in understanding subgroup risk. Future research should prioritize addressing these gaps to improve CMD care."

Journal • Review • Cardiovascular • CNS Disorders • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Obesity • Orthopedics

Hypercholesterolemia as a Causal Risk Factor for COPD: Biomarker Discovery and Therapeutic Implications From NHANES Data. (PubMed, Int J Chron Obstruct Pulmon Dis) - "Bioinformatics analyses pinpointed atorvastatin, fenofibrate, and pravastatin as candidate therapeutics. Analysis of NHANES data demonstrates an inverse association between cholesterol levels and COPD prevalence, with MR confirming a causal relationship. These findings underscore targetable pathways and suggest repurposing statins and fibrates, meriting further mechanistic studies and clinical trials for validation."

Biomarker • Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Dyslipidemia • Immunology • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Tobacco Cessation

Groove Pancreatitis Imitating Hypertriglyceridemic Pancreatitis: Unraveling a Diagnostic Dilemma (ACG 2025) - "Given the CT findings suggestive of GP, an MRI abdomen was obtained which showed distended stomach and duodenum with abnormal thickening of the third part of the duodenum and mild edema along the uncinate process of the pancreas—findings consistent with GP.The patient was started on fenofibrate and atorvastatin. Concurrently, the patient's elevated triglyceride level introduced hypertriglyceridemia as another possible etiology contributing to a mixed clinical picture. Given this overlap and despite the presence of hypertriglyceridemia, imaging was pursued to evaluate for GP based on suggestive CT findings.This case highlights the importance of considering GP in the differential diagnosis in patients particularly when clinical and imaging features deviate from the expected course."

Cardiovascular • Diabetes • Dyslipidemia • Gastrointestinal Disorder • Hypertension • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Type 2 Diabetes Mellitus

Diabetic Ketoacidosis, Hypertriglyceridemia, and Acute Pancreatitis: A Rare but Potentially Fatal Triad Complicated by Pancreatic Pseudocyst (ACG 2025) - "Upon clinical improvement, the patient was discharged on a basal‑bolus insulin, fenofibrate, atorvastatin, and a strict low‑fat diet. Pancreatic pseudocysts usually develop more than four weeks after acute pancreatitis. Day 1 CT abdomen+pelvic with IV contrastFigure: Figure 2. Day 6 repeat CT abdomen+pelvic with IV contrast"

Cardiovascular • Diabetes • Dyslipidemia • Hypertriglyceridemia • Inflammation • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

When Metabolic Stress Meets Genetics: A Triad of DKA, Acute Pancreatitis, and Hypertriglyceridemia in a Patient with LMF1 Mutation (ENDO 2025) - "He had poor adherence to metformin, Jardiance, and pioglitazone, with an A1C of 10.7%...He was discharged on insulin, atorvastatin, and fenofibrate with a diabetes education referral...Data comparing insulin infusion and plasmapheresis for treating HTG in HTG-AP-DKA is limited. Plasmapheresis may be more effective in LPL deficiency cases, warranting further research in the future."

Clinical • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pain • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • LPL

Giant Pancreatic Pseudocyst as a complication of Hypertriglyceridemia-Induced Pancreatitis (ENDO 2025) - "On day tenth, given clinical and biochemical improvement and a multidisciplinary team discussion, patient was discharged on metformin, fenofibrate, atorvastatin, pioglitazone, and vascepa, with plan for GI follow-up for possible necrosectomy. This case reports rare occurrence of HTG-induced necrotizing pancreatitis with the formation of giant pancreatic pseudocyst. It also illustrates the importance of timely intervention and proper management of severe hypertriglyceridemia, to reduce the risk of complications including necrotizing pancreatitis and pseudocyst. Long-term management should be focused on alleviating the effects of metabolic syndrome by addressing related factors like diabetes and obesity."

Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Obesity • Pain • Pancreatitis • Severe Hypertriglyceridemia

FDA endorses 10 more drug products for VAT exemption (Manila Bulletin) - "The newly endorsed VAT-exempt drugs are as follows: High cholesterol: Atorvastatin (as calcium) + Fenobribrate 20 mg/160 mg; Cancer: Tegafur + Gimeracil + Oteracil Potassium 20 mg/5.8 mg/19.6 mg and Tegafur + Gimeracil + Oteracil Potassium 25 mg/7.25 mg/24.5 mg; Diabetes: Metformin Hydrochloride + Teneligliptin (as hydrobromide hydrate) 1 g/20 mg and Metformin Hydrochloride + Teneligliptin (as hydrobromide hydrate) 500 mg/20 mg; Hypertension: Metoprolol tartrate + Ivabradine (as hydrochloride) 50 mg/5 mg and Metoprolol tartrate + Ivabradine (as hydrochloride) 25 mg/5 mg; Hypertension: Metoprolol tartrate + Ivabradine (as hydrochloride) 50 mg/5 mg and Metoprolol tartrate + Ivabradine (as hydrochloride) 25 mg/5 mg; Mental illness: Lamotrigine 5 mg (dispersible/chewable tablet), Lamotrigine 25 mg (oral dispersible tablet), and Lamotrigine 25 mg (tablet)"

Commercial • FDA event • Breast Cancer • CNS Disorders • Colorectal Cancer • Diabetes • Dyslipidemia • Gastric Cancer • Hypertension • Non Small Cell Lung Cancer • Prostate Cancer • Renal Cell Carcinoma

Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia. (PubMed, Cardiol Ther) - P3 | "The FDC therapy of atorvastatin 20 mg/fenofibrate 160 mg achieved a greater percentage reduction in lipid profile than atorvastatin alone. No differences in adverse events were observed between the groups."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Mixed Hyperlipidemia • Type 2 Diabetes Mellitus

LIPOPROTEIN GLOMERULOPATHY WITH NOVEL GENETIC VARIANT- CASE REPORT (ISN-WCN 2025) - "Diagnosis of nephrotic syndrome was made and he was started on prednisolone 2mg/kg/day, Furosemide and advised fluid and salt restriction...Immunosuppression was stopped and child was treated with atorvastatin 20mg + Fenofibrate 80mg, Telmisartan 20mg once daily...To our knowledge, this APOE mutation c.502C>T (p. Arg168Cys) has not been reported in literature and is the youngest patient to develop this disease."

Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hypertension • Metabolic Disorders • Pediatrics • Rare Diseases • APOE • ARG1

Capecitabine-Induced Hypertriglyceridemia Leading to Pancreatitis: A Rare Presentation (ACG 2024) - "Case Description/ A 36-year-old female with ER/PR receptor-negative invasive ductal carcinoma of the breast on pembrolizumab, carboplatin, and capecitabine, presented to the emergency department with epigastric pain...Initiation of fenofibrate and atorvastatin further reduced her triglyceride level to 591 mg/dL six days post-presentation when she was discharged...Figure: Figure 1: Computed Tomography (CT) scan showing acute interstitial edematous pancreatitis. (A) Coronal view; (B) Sagittal view."

Breast Cancer • Dyslipidemia • Gastrointestinal Disorder • Hypertriglyceridemia • Oncology • Pain • Pancreatitis • Solid Tumor

Enhancing intracellular cholesterol efflux in chondrocytes alleviates osteoarthritis progression. (PubMed, Arthritis Rheumatol) - "Our results suggest that restoration of cholesterol homeostasis to a normal state through administration of fenofibrate or AIBP overexpression, both of which induce cholesterol efflux, offers an effective therapeutic option for OA."

Journal • Dyslipidemia • Immunology • Osteoarthritis • Pain • Rheumatology • APOA1

Reduction of Residual Lipid Risk in Patients with Type 2 Diabetes and Mixed Dyslipidemia Treated with a Fixed-Dose Combination of Atorvastatin/Fenofibrate (ADA 2024) - "Patients receiving Atorvastatin/Fenofibrate FDC had a better reduction than monotherapy in non-LDL cholesterol-dependent RRL markers, which translates to a decrease in overall cardiovascular risk for this treatment group."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome (NLA 2024) - "Prior to discharge, she was restarted on atorvastatin, fenofibrate, and omega-3 acid ethyl esters. Managing severe, symptomatic HTG includes NPO status, insulin infusion, and oral lipid lowering therapies; often requiring prolonged hospitalization. Plasmapheresis, though costly and invasive, offers a rapid reduction in TG, symptom resolution, and prevention of HTG-associated complications. Future studies on these treatment modalities can aid in developing inpatient management guidelines for chylomicronemia syndrome."

Cardiovascular • Dyslipidemia • Hypertension • Hypertriglyceridemia • Pain • Pancreatitis • Type 2 Diabetes Mellitus

Triglyceride Tango: when Triglycerides take legs for a spin (ENDO 2024) - "IV fluids were started, and the patient received IV Dilaudid for pain...Endocrine was consulted and recommended initiation of a fenofibrate and atorvastatin. Although the patient was not a diabetic, endocrinology gave 20 units of basal insulin to the patient (Lantus)...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hypertriglyceridemia • Metabolic Disorders • Pain • Pancreatitis